@article {7592,
	title = {Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma},
	journal = {Haematologica},
	volume = {98},
	year = {2013},
	note = {Cited By :16Export Date: 21 February 2017},
	month = {2013},
	pages = {1264 - 1272},
	abstract = {This phase II study is the first prospective evaluation of bortezomib-dexamethasone as second-line therapy for relapsed/refractory multiple myeloma. A total of 163 patients were enrolled to receive four cycles of bortezomibdexamethasone. Patients were investigator-assessed for response at cycle 5 Day 1, then treated as follows: responding patients received another four cycles of bortezomib-dexamethasone, while patients with stable disease were subsequently randomized to sequential treatment with a further four cycles of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide. The primary end point was response to sequential therapy; however, this could not be evaluated because investigator-assessed response rates to bortezomib-dexamethasone after four cycles were high, and an insufficient number of patients were randomized to sequential treatment per protocol. Among all 163 patients, validated best confirmed response rate was 66\%, including 37\% complete/very good partial responses; median response duration was 9.7 months. After a median follow up of 16.9 months, median time to progression and progression-free survival were 9.5 and 8.6 months, respectively; estimated 1-year overall survival was 81\%. Median glomerular filtration rate improved from baseline during treatment. Among 58 patients with baseline glomerular filtration rate below 50 mL/min, 24 had renal responses. Grade 3/4 adverse events included: thrombocytopenia (17\%), anemia (10\%), constipation (6\%), peripheral sensory neuropathy (5\%), and polyneuropathy (5\%). Overall, 57\% of neuropathy events improved/resolved; median time to improvement was 2.1 months. These findings suggest bortezomib-dexamethasone represents an active, feasible second-line treatment option for patients with relapsed/refractory myeloma.. {\textcopyright} 2013 Ferrata Storti Foundation.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881016175\&doi=10.3324\%2fhaematol.2013.084376\&partnerID=40\&md5=248adb51572e2e9a886ef48cc497ae3e},
	author = {Dimopoulos, M.A. and Beksac, M. and Benboubker, L. and Roddie, H. and Allietta, N. and Broer, E. and Couturier, C. and Mazier, M.-A. and Angermund, R. and Facon, T.}
}
